Prospective evaluation of intravitreal bevacizumab for ischemic central retinal vein occlusion

BackgroundAlthough previous studies have evaluated the effect of anti-VEGF therapies for central retinal vein occlusion (CRVO) patients, the majority of previous studies have excluded or included a very small number of patients with ischemic CRVO (iCRVO). The aim of our study is to examine the effects of bevacizumab on macular edema secondary to ischemic central retinal vein occlusion, as well as the effects on central choroidal thickness and best-corrected visual acuity.MethodsIn this prospective, interventional case series, iCRVO was defined by the presence of >= 10 or more disc diameter areas of retinal nonperfusion by fluorescein angiography (FA) and by the presence of a b/a ratio less than 1.5 by full-field electroretinogram (ffERG). Nine eyes with iCRVO received monthly bevacizumab 0.5 mg injections at baseline and months 1 to 5 for a maximum of six injections. Main outcome measures were visual acuity (Snellen), central foveal thickness, and central choroidal thickness as measured by Spectral-Domain Optical Coherence Tomography (SD-OCT) at baseline and at 6 month following initial intravitreal bevacizumab injection. Pairwise t-tests and the Wilcoxon signed-rank test were conducted to compare the outcome measures.ResultsAfter intravitreal administration of bevacizumab, there was a significant reduction of central foveal thickness from 858311 mu m at baseline to 243 +/- 106 mu m at the 6-month follow-up, as well as a significant reduction of central choroidal thickness from 282 +/- 38 mu m at baseline to 227 +/- 56 mu m at the 6-month follow-up (p=0.0006, p=0.0003 respectively). The visual acuity worsened from a median of 1.3 to 1.7 (p=0.02).ConclusionIn patients with iCRVO, intravitreal bevacizumab led to a reduction of central macular edema and central choroidal thickness, but a worsening of visual acuity. Intravitreal bevacizumab reduces macular edema but is not able to overcome the poor prognosis of iCRVO.